CBD Guides

UK trial evidence for CBD in psoriasis: topicals help but oral doesn’t

By the Honest CBD Co team · 3rd September 2026 · Updated 1st October 2026

Topical CBD shows genuine, trial-backed promise for easing itch and redness in psoriasis, while oral CBD has not demonstrated any reduction in plaque severity. A 2025 randomised trial found 60mg daily oral CBD failed to improve PASI scores against placebo, though it eased itch and sleep problems for a few weeks. Topical formulations, tested at lower doses on the skin directly, have fared better in smaller studies. Neither replaces prescribed treatment, and your dermatologist should know before you start.

TL;DR:

Topical CBD shows promise in reducing psoriasis severity and inflammation, with small trials indicating improvements in skin plaques and scalp symptoms.

Oral CBD has not demonstrated any significant impact on plaque severity, with most benefits being temporary and limited to symptom relief.

Delivery method and formulation are critical, as topical products directly contact affected tissue while oral CBD faces pharmacological barriers reducing effectiveness.

Small sample sizes, short follow-up periods, and formulation variability limit the confidence in existing trial results, especially for long-term use.

Talk to your GP or dermatologist before adding CBD to your treatment plan, patch test any topical first, and track your results over a set trial window.

How CBD might work in psoriasis: the mechanisms researchers cite
What the human trials and reviews actually show
Topical versus oral: which one actually fits your symptoms
Safety, side effects and drug interactions: a checklist before you try CBD
How to try CBD for psoriasis safely: a step-by-step trial plan
Scalp psoriasis: what the CBD shampoo evidence actually shows
What to expect: realistic timelines and how to measure it
Dosage guidelines and how often to apply CBD for psoriasis
How CBD compares with corticosteroids and biologics
Legal status and regulation of CBD products for psoriasis patients
Long-term use: what’s still unknown about chronic use
What real-world experiences add to the trial data
Why I think the CBD conversation needs more honesty, not more hype
Try a CBD topical the right way, with Honest CBD Co
Primary studies and reviews referenced in this article
Sources

How CBD might work in psoriasis: the mechanisms researchers cite

Psoriasis is driven by an overactive immune response that tells skin cells to multiply far faster than normal, creating the thickened, scaly plaques that define the condition. CBD’s plausible role comes down to how it interacts with receptors already present in skin tissue, not some novel pathway invented by supplement marketing.

Skin carries its own local endocannabinoid system, including CB1 and CB2 receptors, TRPV ion channels, and PPAR-gamma receptors. CBD engages with several of these simultaneously, which is unusual for a single compound and part of why researchers keep circling back to it. A 2024 narrative review summarising this activity points to three mechanisms that matter for psoriasis specifically:

Cytokine suppression. CBD appears to dampen the release of TNF-alpha and IFN-gamma, two inflammatory messengers heavily implicated in psoriatic plaque formation, partly by modulating NF-kB transcription activity inside skin cells.
Anti-proliferative action on keratinocytes. In vitro work cited in that same review shows CBD slowing the excessive division of keratinocytes, the skin cells that pile up to form psoriasis scales.
Oxidative stress reduction. Preclinical studies have found CBD reduces markers of oxidative damage in keratinocytes taken from psoriatic skin, alongside lower secretion of inflammatory cytokines from peripheral blood cells, according to unpublished preclinical work referenced in dermatology literature.

None of this is settled science. Most of the cytokine and keratinocyte data comes from cell cultures and animal models, not from psoriasis patients using a cream twice a day for three months. It tells you why researchers bothered running human trials at all, but it does not tell you how big the real-world effect is.

Delivery route matters here more than with most active ingredients. Applying CBD directly to a plaque puts it in contact with the exact tissue where TNF-alpha and keratinocyte overactivity are happening, at a concentration that skin absorption can plausibly achieve. Swallowing a CBD oil capsule means the compound has to survive digestion, pass through the liver, and circulate systemically before any of it reaches skin tissue in a meaningful concentration. That pharmacological gap is the main reason topical and oral CBD produce such different trial results, which the next section covers in detail.

Pro Tip: If you’re comparing products, look for the CBD percentage on the label rather than just “CBD infused” wording.

The mechanistic case for CBD in psoriasis is coherent, not proven. It explains why a topical cream might calm an itchy plaque. It does not explain away the disappointing oral trial results, because a receptor interaction in a petri dish and a measurable clinical outcome in a person are two very different things.

What the human trials and reviews actually show

The clinical picture splits sharply along one line: topical CBD has some genuinely encouraging small-trial data, and oral CBD does not.

Small open-label and split-body reports using topical CBD ointments, generally around 2 to 2.5% concentration applied twice daily, have recorded measurable improvements in psoriasis severity index scores over 8 to 12 weeks. Split-body design matters here: researchers treat one plaque with CBD and a comparable plaque on the same patient with a control formulation, which controls for a lot of the individual variation that plagues small dermatology trials. That’s a stronger design than a simple before-and-after photo comparison, though the sample sizes involved remain small enough that a single unusually strong responder can skew results.

What the numbers say: In the largest oral trial to date, itch scores improved significantly by week 8 (p=0.037) and sleep onset latency improved by week 6 (p=0.030), but neither benefit held by week 12, and PASI scores showed no significant difference from placebo at any point (p=0.482).

That trial is the one worth understanding properly, because it is the strongest piece of oral CBD evidence available and it is a genuinely mixed result rather than a clean win or loss. The randomised, double-blind, placebo-controlled study gave participants 60mg of oral CBD daily and tracked PASI, itch, and sleep across 12 weeks. Disease severity did not budge relative to placebo. Quality-of-life measures did move, briefly, then faded. That pattern, a real but temporary symptomatic lift with no change to the underlying disease process, is arguably the most honest single data point in the entire CBD-for-psoriasis conversation.

Scalp disease tells a slightly different story again. A trial of a broad-spectrum CBD shampoo in patients with mild to moderate scalp psoriasis or seborrhoeic dermatitis found significant reductions in trichoscopic inflammation and symptom scores within just two weeks, with tolerability rated highly by participants. Two weeks is fast by dermatology trial standards, and the researchers behind the shampoo work suggest transfollicular delivery, meaning the active ingredient reaching inflamed tissue via hair follicles, may partly explain the quicker response compared with body-plaque topicals.

Reading across all of this, a few limitations deserve equal weight to the positive findings:

Sample sizes are small. Most topical trials run into the dozens of participants, not hundreds, which limits how confidently results generalise.
Formulations vary widely between studies. A 2.5% ointment, a broad-spectrum shampoo, and an oral oil are three different delivery systems, and lumping their results together as “CBD works” oversimplifies what the data actually shows.
Follow-up periods are short. Twelve weeks is common; almost nothing tracks patients for six months or a year, so nobody can say with confidence whether benefits persist or plateau.
Endpoints differ. Some trials measure PASI, others measure symptom scores, others measure itch on a visual analogue scale, which makes cross-study comparison harder than headlines suggest.

None of that erases the topical findings. It does mean treating “CBD helps psoriasis” as a settled fact would be getting ahead of what dermatology researchers themselves are willing to claim.

Topical versus oral: which one actually fits your symptoms

The honest answer depends entirely on what you’re trying to fix. Localised plaques and scalp involvement respond to direct contact; systemic symptoms like poor sleep or generalised stress don’t have a plaque to apply cream to, so oral CBD gets tried there instead, with the important caveat that it hasn’t been shown to touch the underlying disease.

Topical formats cover a wider range than most people expect:

Ointments and salves, typically the format used in the 2 to 2.5% concentration trials, tend to sit on the skin longer and suit thick, stubborn plaques. Our own CBD Body Salve (500mg CBD in a 50ml tin, £19.99) is this format, handcrafted for external use.
Creams, lighter and faster-absorbing, work better for larger body areas or sensitive skin that reacts to heavier bases.
Medicated shampoos, the format behind the fastest reported results, target scalp involvement specifically and benefit from transfollicular delivery.

Oral formats, mainly oils and capsules, get chosen by people managing the sleep disruption and stress that often accompany chronic psoriasis, rather than by people expecting the plaques themselves to shrink. That distinction is worth holding onto, because it’s the difference between a reasonable use case and a false expectation.

Formulation type matters beyond just topical versus oral. Full-spectrum products retain the plant’s other cannabinoids and terpenes alongside CBD, broad-spectrum versions strip out THC while keeping other compounds, and isolate is CBD alone with nothing else. Trial data hasn’t isolated which spectrum type performs best for skin specifically, so this is more a personal-preference and product-transparency question than a clinical one. Carrier oils and excipients also affect how well a topical is tolerated. A coconut-oil or hemp-seed-oil base tends to sit well on most skin types, whereas heavily fragranced or alcohol-based formulations can aggravate already-compromised psoriatic skin. Our salve uses a shea butter, coconut oil and beeswax base, with lavender and ylang ylang essential oils; if coconut is a problem for you, our guide to coconut allergy and CBD covers what to check before buying any CBD product.

For practical application, once or twice daily matches the frequency used in the topical trials, applied directly to clean, dry plaques. Coordinate timing with any topical steroid or vitamin D analogue your dermatologist has prescribed, since layering multiple active products without guidance risks reducing absorption of either one.

Pro Tip: Introduce a new topical one product at a time. If you add a CBD cream, a new moisturiser, and a fragrance change to your routine in the same week, you’ll have no way of knowing which one caused any improvement or flare.

Safety, side effects and drug interactions: a checklist before you try CBD

CBD’s side effect profile in trials has generally looked mild, often comparable to placebo, but “generally mild” is not the same as “risk-free”, and psoriasis patients frequently take other medications that complicate the picture.

Watch for gastrointestinal upset, fatigue, or mood changes. These are the most commonly reported adverse effects across CBD trials, usually manageable but worth logging if they appear.
Check for drug interactions via the CYP450 enzyme pathway. CBD is metabolised through the same liver enzyme system as many prescription drugs, including some blood thinners and immunosuppressants that psoriasis patients on systemic therapy may be taking. A pharmacist or GP can flag this quickly; don’t guess. Our guide to CBD and blood pressure medication covers how these enzyme interactions work in more detail.
Exercise particular caution during pregnancy, breastfeeding, or in children. Evidence in these groups is too thin to support any confident safety claim, so these are situations where CBD should be avoided unless a clinician says otherwise.
Be cautious with serious liver disease. Because CBD is processed through the liver, existing hepatic impairment changes how the compound is cleared from the body.
Buy from a supplier with a track record. Choose an established UK supplier, check the ingredient list is specific rather than vague, and confirm the THC content sits within the UK legal limit of 1mg per container.

If you’re taking biologics or other systemic psoriasis treatments, mention CBD to your prescribing dermatologist specifically, rather than assuming a topical cream is too minor to be worth flagging. It usually is minor, but “usually” is exactly the word that makes a five-minute conversation worthwhile.

How to try CBD for psoriasis safely: a step-by-step trial plan

A structured trial beats an impulse purchase, largely because psoriasis fluctuates on its own and you need a way to tell a genuine improvement from a coincidental good week.

Talk to your dermatologist or GP first and write down your current treatment regimen. This matters most if you’re on topical steroids, vitamin D analogues, or systemic therapy, since your clinician needs the full picture to advise on interactions or timing.
Choose a lab-tested product and patch test it for 48 to 72 hours. Apply a small amount to unaffected skin, ideally the inner forearm, and watch for redness, itching, or swelling before using it on active plaques.
Set a defined trial period and track it properly. For topicals, 2 to 12 weeks depending on the formulation is realistic; take baseline photographs, score your itch on a simple 0 to 10 scale, and repeat both at set intervals rather than relying on memory.
Decide your stop criteria before you start, not after. Discontinue and seek care immediately if you notice signs of infection, if plaques visibly worsen, or if there’s no measurable change by your predefined checkpoint, typically the 8 to 12 week mark for topicals.

Pro Tip: Photograph the same plaque under the same lighting each time, ideally near a window at the same time of day. Phone cameras vary their colour processing between shots taken in different light, which can make a plaque look falsely better or worse than it actually is.

This structure exists to catch placebo effects and normal disease fluctuation, both of which are common enough in psoriasis to fool an unstructured trial completely.

Scalp psoriasis: what the CBD shampoo evidence actually shows

Scalp psoriasis behaves differently from body plaques, and the shampoo trial data reflects that. Patients with mild to moderate scalp psoriasis or seborrhoeic dermatitis using a broad-spectrum CBD shampoo saw significant reductions in trichoscopic inflammation and symptom scores within two weeks, with tolerability rated highly throughout the trial.

The likely explanation for that speed is transfollicular delivery: hair follicles offer a more direct route into inflamed tissue than skin absorption alone provides on the body. That’s a plausible pharmacological explanation rather than a guaranteed one, but it lines up with why scalp results have consistently outpaced body-plaque topical results in the available trials.

Practical points for anyone switching shampoos:

Give a new shampoo at least two weeks before judging it, matching the trial’s own timeline rather than switching again after two washes.
Consider complementary active ingredients such as ketoconazole if fungal or seborrhoeic overlap is part of your scalp presentation, something worth raising with a dermatologist rather than guessing.
Use gentle application technique. Massage into the scalp rather than the hair shaft, leave it on for the manufacturer’s recommended contact time, and avoid vigorous scratching even if it itches, since scratching alone can worsen scalp plaques independently of any product.

One caution matters here specifically: if you’re already using a medicated topical steroid solution on your scalp, check with your prescriber before adding a CBD shampoo into the same routine. Combining active topical treatments without guidance risks either reduced absorption of the steroid or unnecessary skin irritation from product interaction, the same stacking risk that applies to body topicals.

What to expect: realistic timelines and how to measure it

Expectations matter as much as the product itself here. Symptomatic relief, meaning itch reduction and general comfort, has shown up within 1 to 2 weeks for some topical and shampoo formulations. Actual lesion improvement, the kind visible in photographs and measurable by PASI, is a longer game, generally requiring 8 to 12 weeks even in the more encouraging small trials.

Oral CBD’s benefits follow a different, more disappointing pattern. The strongest available RCT recorded itch improvement peaking around week 8 and sleep improvement around week 6, both fading by week 12. If you’re trying oral CBD specifically for sleep or itch, treat any early benefit as possibly temporary rather than assuming it will hold.

Track three simple things throughout any trial: dated photographs of the same plaque under consistent lighting, a weekly itch score from 0 to 10, and a basic lesion checklist noting scale, redness, and thickness. If none of the three have moved by your predefined checkpoint, that’s your signal to stop or revise the approach rather than continuing indefinitely on hope.

Dosage guidelines and how often to apply CBD for psoriasis

There’s no officially established dosing standard for CBD in psoriasis, which is worth stating plainly rather than dressing up with false precision. The most useful reference point is what trials have actually used rather than manufacturer suggestions, which vary wildly and aren’t always tied to evidence.

Higher concentrations aren’t automatically better; they simply haven’t been tested as thoroughly, so you’d be trialling an unknown rather than following a data point.

For oral use, the randomised trial that produced the clearest data used 60mg per day, split or single dose depending on the product. That’s a reasonable starting reference if you and your clinician decide oral CBD is worth trying for sleep or itch, though remember this dose showed no effect on plaque severity itself.

For wider context, the FSA advises healthy adults to keep CBD food-supplement intake to about 10mg a day. That advice is precautionary, not a legal limit or a maximum: the FSA’s own figure was 70mg a day until autumn 2023, and clinical research routinely uses far higher doses than either, this trial’s 60mg included. In our view the current figure is out of step with real-world use; many regular users settle between 25mg and 100mg or more a day once they’ve found their level.

Start low and hold steady for your full trial window rather than escalating the dose every few days out of impatience. Constant dose-chasing makes it impossible to know whether a change in symptoms came from the product, the dose increase, or simple day-to-day fluctuation in your psoriasis. If a topical product isn’t showing any change in itch or comfort by around the 4-week mark, that’s a reasonable point to reassess rather than persisting blindly to 12 weeks.

How CBD compares with corticosteroids and biologics

Corticosteroid creams and biologic injections work through mechanisms with decades of large-scale trial data behind them, and that gap in evidence volume is the single biggest difference between them and CBD.

Topical corticosteroids suppress inflammation quickly and reliably, with well-established dosing and a known side-effect profile including skin thinning with prolonged use. Biologics target specific immune pathways, such as IL-17 or IL-23, and can clear plaques almost completely in many patients, backed by trials involving thousands of participants over multiple years. CBD, by contrast, has trial data measured in dozens of participants and weeks of follow-up, not years.

That doesn’t make CBD useless. It makes it a different category of tool. Where corticosteroids and biologics aim to treat the underlying disease process, CBD’s best-supported role right now is symptomatic, easing itch and improving comfort, particularly on the scalp, without the skin-thinning risk that comes with long-term steroid use. Some patients use CBD topicals alongside prescribed treatment specifically to reduce the frequency of steroid application, though that approach should be discussed with a dermatologist rather than self-managed.

Nobody currently has evidence to support swapping a biologic for CBD, and no dermatologist worth listening to would recommend it. The realistic conversation is about where CBD might sit as an add-on, not a replacement, for standard psoriasis care.

Legal status and regulation of CBD products for psoriasis patients

CBD derived from hemp is legal to sell and buy across the UK provided it contains no more than 1mg of THC per container, regardless of the product’s overall size, under Home Office guidance for CBD products. That’s a different threshold from some other markets, so imported products bought from overseas retailers may not meet UK requirements even if legal where they were made.

No UK or European regulatory body has approved CBD as a treatment for psoriasis specifically. It’s sold and regulated as a food supplement or cosmetic ingredient, not a licensed medicine, which means manufacturers cannot legally claim it treats, cures, or prevents any disease on packaging or in marketing. That regulatory gap is precisely why patient organisations and dermatologists recommend discussing CBD with a clinician as one part of a wider treatment plan, rather than treating it as an approved alternative to prescribed care.

Buying from an established UK supplier matters more for psoriasis patients than for general wellness users, since you’re applying product directly to inflamed, already compromised skin. Look for a specific ingredient list and a trading history you can check. We’ve been making our range in small batches in the UK since 2018; our CBD is lab tested at source and we’re happy to share the certificates of analysis.

Long-term use: what’s still unknown about chronic use

Psoriasis is a lifelong condition for most people who have it, which raises an obvious question trial data hasn’t really answered: what happens if you use CBD for years rather than weeks?

Almost every trial referenced in dermatology literature runs for 12 weeks or less. Nobody has published data tracking topical or oral CBD use in psoriasis patients over one, five, or ten years, so long-term safety and long-term efficacy are both genuinely unknown rather than reassuringly established. That’s not a reason for alarm, since nothing in the short-term data suggests cumulative harm, but it is a reason to keep monitoring your own skin and general health rather than assuming a product that worked at week 8 will keep working, unchanged, at year three.

Practical long-term considerations worth building into your routine: periodic liver function checks if you’re using oral CBD alongside other medications processed through the liver, occasional product reformulation checks (manufacturers change carrier oils and excipients more often than people expect), and honest reassessment of whether the product is still doing anything. Psoriasis severity fluctuates with stress, season, and illness independent of any treatment, so a plaque that flares in winter after two good years on a topical isn’t necessarily a sign the product has stopped working. It might just be January.

What real-world experiences add to the trial data

Clinical trials measure averages across groups; individual experience is messier and more varied, which is exactly what you’d expect from a skin condition known for fluctuating unpredictably even without any treatment change.

Patient-facing commentary consistently echoes the trial pattern rather than contradicting it: people report itch relief and comfort from topical products more often and more confidently than they report visible plaque clearance. That consistency between structured trial data and informal patient accounts is reassuring in one specific sense, it suggests the topical itch-relief effect is probably real, not a trial artefact, even though nobody has proven it works for the disease process itself.

What real-world use adds beyond the trials is mostly about product variability. People trying CBD for psoriasis outside a controlled study are choosing between dozens of concentrations, carrier oils, and full-spectrum versus isolate formulations that no single trial has directly compared. That’s precisely why the safety checklist and structured trial plan covered earlier in this article matter as much as the underlying science: a good process protects you from drawing the wrong conclusion from a product that happened to be poorly formulated, badly timed, or simply wrong for your particular presentation.

Why I think the CBD conversation needs more honesty, not more hype

The gap between what CBD promises on product packaging and what the actual trial data shows is wider for psoriasis than for almost any other condition I’ve looked into. Topical CBD has real, if modest, trial support. Oral CBD, the format most heavily marketed for general wellness, has the weakest evidence of the lot for this specific condition. That inversion, the more commonly sold format being the less well-supported one, doesn’t get said often enough.

What frustrates me most about how this topic gets covered elsewhere is the casual conflation of “shows promise in a small trial” with “works.” The oral RCT is a genuinely useful piece of research precisely because it’s honest: real short-term symptom relief, no disease-modifying effect, benefits that faded by week 12. That’s not a failure of the study. That’s the study doing its job and giving us an answer we might not have wanted.

Where I land is this: CBD, used topically, lab-tested, and folded into a plan your dermatologist knows about, is a reasonable thing to trial for itch and scalp comfort. Treating it as a psoriasis treatment in the sense that biologics or corticosteroids are treatments oversells evidence that simply isn’t there yet. Anyone selling CBD on the promise of clearer plaques is selling ahead of the data, full stop.

Richard

Try a CBD topical the right way, with Honest CBD Co

If the trial plan above has you ready to try a topical, the product you choose matters as much as the plan itself. Honest CBD Co is a husband-and-wife business in Bolton, handcrafting small batches in the UK since 2018 and rated Excellent on Trustpilot across 732 reviews.

The natural fit for the topical evidence covered here is our CBD Body Salve: 500mg of CBD in a 50ml tin for £19.99, THC-free, handcrafted on a shea butter, coconut oil and beeswax base, with lavender and ylang ylang essential oils, and made for external use on skin exactly like this. If you’re weighing an oral option for sleep or general comfort alongside it, our Full Spectrum CBD Oil comes in 10% (£25.99) and 20% (£37.99) strengths in 10ml bottles, and UK delivery is free. Whichever format you choose, patch test it first, keep your dermatologist informed, and track your results properly over a set trial window.

Primary studies and reviews referenced in this article

The clinical claims throughout this piece draw on three core sources. The oral CBD randomised controlled trial provides the PASI, itch, and sleep data referenced in the evidence and dosage sections. The 2024 mechanism review underpins the biological explanations in the mechanisms section. The broad-spectrum shampoo trial supports the scalp psoriasis findings.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.